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Mycobacterium avium causes respiratory disease in susceptible individuals, as well as disseminated infections in immunocom-
promised hosts, being an important cause of morbidity andmortality among these populations. Current therapies consist of a
combination of antibiotics taken for at least 6 months, with nomore than 60% overall clinical success. Furthermore, mycobacte-
rial antibiotic resistance is increasing worldwide, urging the need to develop novel classes of antimicrobial drugs. One potential
and interesting alternative strategy is the use of antimicrobial peptides (AMP). These are present in almost all living organisms
as part of their immune system, acting as a first barrier against invading pathogens. In this context, we investigated the effect of
several lactoferrin-derived AMP againstM. avium. Short peptide sequences from both human and bovine lactoferricins, namely,
hLFcin1-11 and LFcin17-30, as well as variants obtained by specific amino acid substitutions, were evaluated. All tested peptides
significantly inhibited the axenic growth ofM. avium, the bovine peptides being more active than the human. Arginine residues
were found to be crucial for the display of antimycobacterial activity, whereas the all-D-amino-acid analogue of the bovine se-
quence displayed the highest mycobactericidal activity. These findings reveal the promising potential of lactoferricins against
mycobacteria, thus opening the way for further research on their development and use as a new weapon against mycobacterial
infections.
The genus Mycobacterium includes several species capable ofcausing disease in humans and other animals. Mycobacterium
tuberculosis is one of the most deadly human pathogens, killing 1
million to 2 million people every year (1), while Mycobacterium
avium and Mycobacterium intracellulare are frequent opportunis-
tic pathogens of immunosuppressed individuals and people with
chronic respiratory distress (2, 3). Equipped with a complex lipid-
rich cell envelope and adapted to proliferate inside the host’s mac-
rophages, mycobacteria tend to cause persistent infections, which
are difficult to cure, requiring long treatment regimens that rely
on the combination of several drugs. The increasing emergence of
drug-resistant strains of mycobacteria makes the treatment of
these diseases even more challenging (1).
The vast array of antimicrobial peptides (AMP) produced by
virtually all living organisms as natural barriers against infection is
a new and promising source of potential antimicrobial weapons.
Although they have little sequence homology, the vast majority of
AMP contain a high proportion of hydrophobic and cationic
amino acids, and when in contact with bacterial membranes, they
adopt amphipathic structures (4). The fact that AMP are active
against a wide variety of microorganisms, combined with the ob-
servation that both the L and D enantiomers are active, supports
the notion that the target of these peptides is a general structure
conserved across different bacterial species, such as the cytoplas-
mic membrane (5, 6). Thus, it is thought that electrostatic attrac-
tion is responsible for the initial approach between the cationic
peptide and the negatively charged phospholipids usually present
at the pathogen’s surface (4). Downstream events that lead to bac-
terial killing are not yet fully understood (4, 6). Acting in such a
fundamental and conserved biological target as the bacterial
membrane, AMP are believed to be less prone to the development
of secondary microbial resistance than other types of antibiotics
(4, 7). Therefore, a deeper understanding of the mechanisms of
action of AMP, along with the establishment of structure-activity
relationships, is an essential step toward the identification and
development of more active molecules with improved therapeutic
characteristics and possibly higher specificity toward pathogens of
interest.
Lactoferricins are naturally occurring peptides, formed by the
cleavage of the highly cationic N1 terminal domain of the iron-
binding protein lactoferrin. Bovine lactoferricin is composed by
25 amino acids, corresponding to residues 17 to 41 in the native
protein (5, 8), and has broad-spectrum antimicrobial activity (5,
9–15). A shorter version of bovine lactoferricin containing amino
acids 17 to 30 (LFcin17-30) was found to have even higher anti-
microbial activity (16). A human peptide with the first 11 amino
acids from human lactoferrin (hLFcin1-11) was also demon-
strated to be active against a great variety of bacteria, including
antibiotic-resistant strains, and fungi, especially Candida albicans
(17–21), and was already used in different preclinical and clinical
trials, where its overall safety was proved (20, 22).
In the present work, we investigated the activity against M.
avium of hLFcin1-11 and LFcin17-30, as well as peptides obtained
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from these by specific amino acid substitutions, to test the im-
portance of various factors on the potency of AMP against that
pathogen.
MATERIALS AND METHODS
Peptides. Human lactoferricins (hLFcin1-11 and hLFcin1-11 all K) (Ta-
ble 1) were prepared as C-terminal amides by standard Fmoc/tBu [1-(9H-
fluoren-9-yl)-methoxycarbonyl)/tert-butyl chemistry] solid-phase pep-
tide synthesis on a Liberty1 microwave (MW) peptide synthesizer (CEM
Corporation, Mathews, NC, USA) (23). Briefly, Fmoc-Rink-amide resin
(NovaBiochem, Switzerland) was preswelled for 15 min in N,N-dimeth-
ylformamide (DMF) (VWR International, Portugal) and then transferred
into the MW reaction vessel. The initial Fmoc deprotection step was car-
ried out using 20% piperidine in DMF containing 0.1 M 1-hydroxyben-
zotriazole (HOBt) (Sigma-Aldrich, Germany) in two MW irradiation
pulses: 30 s at 24 W plus 3 min at 28 W, with the temperature in both cases
being no higher than 75°C. The Fmoc-protected C-terminal amino acid
(Bachem, Switzerland) was then coupled to the resin, using 5 molar equiv-
alents (eq) of the Fmoc-protected amino acid in DMF (0.2 M), 5 eq of 0.5
M N,N,N=,N=-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluo-
rophosphate/HOBt in DMF, and 10 eq of 2 M N-ethyl-N,N-diisopropyl-
amine (DIPEA) (Sigma-Aldrich, Germany) in N-methylpyrrolidone
(NMP) (VWR International, Portugal); the coupling step was carried out
for 5 min at 35-W MW irradiation, with a maximum temperature reach-
ing 75°C. The remaining amino acids were sequentially coupled in the
C¡ N direction by means of similar deprotection and coupling cycles,
except for incorporation of the following: (i) Fmoc-Arg(Pbf)-OH, whose
coupling was done in two steps, 25 min with no MW irradiation (room
temperature), followed by 5 min of coupling at 25 W, and (ii) Fmoc-
Cys(Trt)-OH and Fmoc-Trp(Boc)-OH, both also coupled in two steps,
first 2 min of coupling without MW irradiation (room temperature) and
then 4 min of coupling at 25 W, with the maximum temperature reaching
50°C. Following completion of sequence assembly, the peptides were re-
leased from the resin with the concomitant removal of side chain protect-
ing groups, by a 3-h acidolysis at room temperature using a trifluoroacetic
acid (TFA) (VWR International, Portugal)-based cocktail containing tri-
isopropylsilane (TIS) (Sigma-Aldrich, Germany) and water as scavengers
(TFA-TIS-H2O, 95:2.5:2.5 [vol/vol/vol]). Crude products were purified
by reverse-phase (RP) liquid chromatography on a Vydac C18 column
(238TPB1520; Vydac, Hesperia, CA, USA) to a purity of at least 95%, as
confirmed by high-performance liquid chromatography (HPLC) analysis
on a Hitachi-Merck LaChrom Elite system equipped with a quaternary
pump, a thermostated (Peltier effect)-automated sampler, and a diode-
array detector (DAD). Pure peptides were quantified by UV absorption
spectroscopy (Helios Gama, Spectronic Unicam), and their molecular
weights were confirmed to be as expected by electrospray ionization/
ion trap mass spectroscopy (ESI/IT MS) (LCQ-DecaXP LC-MS sys-
tem; ThermoFinnigan).
Bovine lactoferricins (LFcin17-30, D-LFcin17-30, LFcin17-30 all R,
and LFcin17-30 all K) (Table 1) were synthesized by solid-phase peptide
synthesis using Fmoc-protected amino acids (Orpegen Pharma GmbH,
Heidelberg, Germany) in a Syro II synthesizer (Biotage, Uppsala, Sweden)
as described previously (24). Peptides were purified to a purity of at least
95% by semipreparative RP-HPLC (Jasco Corporation Tokyo, Japan) on
a Vydac C18 column (218MS510; Vydac, Hesperia, CA, USA), and the
authenticity of the peptides was confirmed by matrix-assisted laser de-
sorption ionization–time of flight (MALDI-TOF) mass spectrometry on a
Microflex LRF mass spectrometer equipped with an additional gridless
reflectron (Bruker Daltonik, Bremen, Germany) as described previously
(25).
All purified peptides were freeze-dried, after which peptide stock so-
lutions were prepared in phosphate-buffered saline (PBS) (pH 7.4) and
stored at20°C until use.
Bacteria. The strains of Mycobacterium avium used in this study were
clinical isolates. Strain 2447 smooth transparent variant (SmT) was pro-
vided by F. Portaels (Institute of Tropical Medicine, Antwerp, Belgium);
strains 2-151, either SmT or SmD (smooth-domed), was provided by J.
Belisle (Colorado State University, Fort Collins, CO, USA).
Mycobacteria were grown to mid-log phase in Middlebrook 7H9 me-
dium (Difco, Sparks, MD) containing 0.05% of Tween 80 (Sigma, St.
Louis, MO) and 10% of ADC supplement (albumin-dextrose-catalase) at
37°C. Bacteria were harvested by centrifugation, washed twice with saline
containing 0.05% Tween 80, resuspended in the same solution, and briefly
sonicated in order to disrupt bacterial clumps. The suspension was stored
in aliquots at 80°C until use. Just before use, an aliquot was quickly
thawed and diluted to the appropriate concentration.
Effect of antimicrobial peptides on the viability of M. avium in ax-
enic cultures. M. avium was grown in Middlebrook 7H9 medium to ex-
ponential phase (bacterial growth was monitored by measuring the opti-
cal density at 600 nm). Bacteria were seeded at 106 CFU per well into
96-well flat bottom plates and incubated with the peptides in a final vol-
ume of 200 l. Each condition was tested in triplicate. The plates were
incubated at 37°C in a humid atmosphere. After 1, 2, 4, or 7 days of
incubation, bacterial viability was measured by a CFU assay. A bacterial
suspension from each well was serially diluted in water containing 0.05%
Tween 80. The dilutions were plated in Middlebrook 7H10 agar medium
(Difco, Sparks, MD) and supplemented with OADC (oleic acid-albumin-
dextrose-catalase), and the colonies were counted after 7 days at 37°C. The
TABLE 1 Antimicrobial activities of lactoferricin peptides against Mycobacterium avium
Peptide Amino acid sequence Mol wta Chargeb
Activity (M) (mean SD) against M. avium strainc
2447 SmT 2-151 SmT 2-151 SmD
IC50 IC90 IC50 IC90 IC50 IC90
hLFcin1-11 GRRRRSVQWCA 1,374 5 15.8 4.5 34.6 22.4 11.0 4.1 65.8 19.3 15.2 2.9 37.9 15.9
hLFcin1-11 all K GKKKKSVQWCA 1,262 5 39.1 6.9d
LFcin17-30 FKCRRWQWRMKKLG 1,923 6 14.2 1.5 18.9 4.0 8.0 1.5 22.8 9.1 12.4 0.3 21.5 4.0
D-LFcin17-30 FKCRRWQWRMKKLG 1,923 6 10.7 0.9e 14.4 1.9
LFcin17-30 all K FKCKKWQWKMKKLG 1,839 6 18.0 2.1e,f,g 34.4 8.2e,f
LFcin17-30 all R FRCRRWQWRMRRLG 2,007 6 10.8 1.6e 19.3 4.8
a Molecular weight.
b Calculated overall charge at pH 7.0.
c Each value represents the average for at least three independent experiments, with the corresponding SD indicated. IC50 is the peptide concentration that inhibits 50% of
mycobacterial viability at 7 days of incubation. IC90 is the peptide concentration that inhibits 90% of mycobacterial viability at 7 days of incubation.
d P 0.0001 (compared to results for the parental peptide, hLFcin1-11).
e P 0.05 (compared to results for the parental peptide, LFcin17-30).
f P 0.05 (compared to results for LFcin17-30 all R, by cross-comparison within the bovine peptides).
g P 0.0001 (compared to results for hLFcin1-11 all K, by cross-comparison within all peptides).
Silva et al.
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difference, in terms of log10 CFU/ml, between the first and the last days of
incubation was designated “log increase.”
IC50 and IC90 (peptide concentration that inhibits 50% or 90% of
mycobacterial growth after 7 days of incubation) values were obtained by
fitting CFU data through a four-parameter dose-response sigmoidal curve
using the GraphPad Prism software program (GraphPad Software Inc., La
Jolla, CA). The reported final values correspond to the average of at least
three independent experiments, with the corresponding standard devia-
tion (SD) indicated.
Statistical analysis was performed with GraphPad Prism software us-
ing one-way analysis of variance (ANOVA) with adjustment for multiple
comparisons in two ways: (i) comparing each value to a control (the
corresponding parental peptide) and (ii) performing cross-comparisons
among all peptides (within each family). The statistical significance, ad-
justed P value, and confidence intervals were obtained through the Bon-
ferroni method for a chosen 95% significance.
SEM.M. avium 2447 SmT was grown in Middlebrook 7H9 medium to
exponential phase. Approximately 106 CFU of bacteria were incubated
with the peptides (25 M) for 2 days at 37°C. After incubation, cytospin
centrifugation (1,000 rpm, 2 min) (Cytospin 4; Thermo Scientific) was
used to concentrate the bacteria in glass coverslips previously coated with
APES (3-aminopropyltriethoxysilane) to promote bacterial adherence.
Bacteria were fixed with 2.5% glutaraldehyde solution in 0.1 M sodium
cacodylate buffer (supplemented with 5 mM MgCl2 and 5 mM CaCl2;
pH  7.2) for 2 h, followed by postfixation with 1% osmium tetroxide
(OsO4) in 0.1 M sodium cacodylate buffer (1 h). Bacteria were then de-
hydrated by successive incubations with increasing concentrations of eth-
anol (10 to 100%), dried in a critical point dryer (CPD7501; Polaron), and
sputter coated with a gold/palladium thin film (50 s with a 15-mA current)
using SPI Module sputter coater equipment. The scanning electron mi-
croscopy (SEM) exam was performed using a high-resolution (Schottky)
environmental scanning electron microscope with X-ray microanalysis
and electron backscattered diffraction analysis: Quanta 400 FEG ESEM/
EDAX Genesis X4M.
TEM. A suspension of M. avium 2447 SmT in exponential growth
phase was incubated with the peptides (25 M) for 2 days at 37°C. Bacte-
ria were fixed with a 4% formaldehyde and 1.25% glutaraldehyde solution
in 0.1 M sodium cacodylate buffer (supplemented with 5 mM MgCl2 and
5 mM CaCl2; pH 7.2) overnight at 4°C (first 3 h at room temperature),
followed by postfixation with 1% osmium tetroxide (OsO4) in 0.1 M
sodium cacodylate buffer (1 h) and 1% uranyl acetate in water (30 min),
gradually dehydrated in ethanol (25 to 100%), included with propylene
oxide, and embedded in Epon resin (26, 27). Ultrathin sections were
stained with lead citrate and uranyl citrate for 15 min each, and the sam-
ples were observed and photographed in a Jeol JEM-1400 transmission
electron microscope (TEM).
RESULTS
Antimycobacterial activity of lactoferricin peptides. Human
and bovine lactoferricin peptides (hLFcin1-11 and LFcin17-30)
were evaluated for their antimicrobial activities against three dif-
ferent strains of M. avium (2-151 SmT, 2447 SmT, and 2-151
SmD) (28). Both peptides were active against the three strains in
axenic cultures, with an IC50 of 15 M (Table 1). The bovine
peptide tended to be more active than the human one, exhibiting
lower IC90 values for all M. avium strains. The activities of each
peptide were similar between the M. avium strains (Table 1).
Arginine residues were reported to be critical for the antimi-
crobial activity of lactoferricins (5, 8, 29). hLFcin1-11 has four
arginine residues, and LFcin17-30 has three (Table 1). In order to
investigate whether these residues were important for the display
of antimycobacterial activity, we synthesized and tested lactoferri-
cin analogues in which arginine residues were replaced by lysine
(all-K variants). Lysine was chosen because it has the same charge
as arginine, and hence any differences in activity would not be
attributable to the alteration of overall positive charge. Since bo-
vine LFcin17-30 has three lysine residues, we also tested a variant
of this peptide in which all lysines were replaced by arginines
(all-R variant).
When tested against M. avium 2447 SmT in axenic culture, the
all-K variants of each peptide were significantly less active than the
corresponding original peptide (Table 1) (P 0.0001 for IC50 for
human peptides; P 0.0329 for IC50 and P 0.0074 for IC90 for
bovine peptides). Conversely, the all-R variant of LFcin17-30 was
slightly more active than the original peptide (Table 1) (for IC50,
P 0.0377). Of note, even in the all-K variants, the bovine peptide
exhibited a stronger antimicrobial activity than the human pep-
tide (P 0.0001) (Table 1).
Given that one of the limitations of therapeutic applications of
peptides is their sensitivity to proteolysis, we thought it would be
interesting to know whether replacement of all native amino acids
in LFcin17-30 by their D enantiomers (less prone to degradation)
would preserve the peptide’s activity against M. avium. Remark-
ably, the all-D LFcin17-30 sequence (D-LFcin17-30) was found to
be significantly more active than the corresponding native peptide
(Table 1) (for IC50, P 0.0455).
We observed in all cases an abrupt decrease in mycobacterial
viability at peptide concentrations around 12.5 M, which trans-
lated into very close values for IC50 and IC90 (Table 1). This sug-
gested that a critical concentration threshold may exist for the
peptides to exert their activity. To test this hypothesis, we assessed
the effect of the human and bovine parental peptides, hLFcin1-11
and LFcin17-30, on M. avium 2447 SmT using narrower concen-
tration intervals in the 12.5 to 25 M range. As shown in Fig. 1,
this experiment confirmed the existence of a threshold concentra-
tion and further showed that the dose-effect correlation is differ-
ent for the two peptides. For hLFcin1-11, there is a gradual de-
crease in the viability of M. avium as the peptide concentration
increases, whereas for LFcin17-30, there is a critical inhibitory
concentration above which the increase in the peptide concentra-
tion has no further effect on mycobacterial viability.
To assess in detail the time dependence of the action of lacto-
ferricin peptides against M. avium 2447 SmT, the antimicrobial
activity was determined by CFU at the end of 1, 2, and 4 days of
FIG 1 Direct effect of human and bovine lactoferricin onM. avium viability at
7 days of incubation. M. avium 2447 SmT was incubated with hLFcin1-11 or
LFcin17-30 at 0, 6.25, 12.5, 15, 17.5, 20, 22.5, 25, 50, and 100 M concentra-
tions. M. avium viability was determined by measuring CFU after 7 days of
incubation. Statistical analysis was performed using one-way ANOVA (Bon-
ferroni test): , P  0.001. The results of one experiment out of three are
shown.
Mycobactericidal Activity of Lactoferricin Peptides
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incubation. No significant effects were seen up to 1 day. All peptides
showed significant inhibitory activity after 2 days of incubation at
12.5 M (Fig. 2) and 25 M (not shown). For the most active pep-
tides (hLFcin1-11, LFcin17-30, D-LFcin17-30, and LFcin17-30 all R),
mycobacterial death was observed at 4 days (Fig. 2).
Similar to what was observed at 7 days of incubation, at shorter
times the bovine peptides tended to be more active than the hu-
man ones, and the peptides with arginines (human or bovine)
were more active than those with lysines.
Surface and ultrastructural alterations inM. avium induced
by lactoferricins. To gain a better understanding of the mecha-
nisms of antimicrobial action of lactoferricin peptides against M.
avium, we performed scanning electron microscopy (SEM) and
transmission electron microscopy (TEM) to identify surface and
ultrastructural alterations in the bacteria upon peptide treatment.
After 2 days of incubation with lactoferricins at 25M, SEM anal-
ysis of M. avium 2447 SmT revealed overall shape deformations
(Fig. 3, left panel, arrow), increased roughness of the bacterial
surface, and the accumulation of biological material outside the
cells (Fig. 3, left panel, arrowhead), this last suggesting leakage of
intracellular content. Ultrastructural alterations were also seen us-
ing TEM, namely, condensation of cytoplasmic dense material,
such as proteins (Fig. 3, right panel, empty arrow), once again with
the suggestion of leakage of intracellular material, indicated by
accumulation of material extracellularly (Fig. 3; right panel, ar-
rowhead), as well as translucent cytoplasm and a high number of
“ghost” cells (Fig. 3, right panel, asterisk). In agreement with the
previous results for activity, the bovine peptides induced more
severe structural alterations in the bacteria than the human ones,
especially D-LFcin17-30 and LFcin17-30 all R (Fig. 3).
DISCUSSION
Considering the potential of AMP as new alternative therapies to
fight infectious diseases and the urgent need to develop more ef-
ficient therapies for infections caused by mycobacteria, we tested
several lactoferricin peptides against Mycobacterium avium. Aside
from the antimicrobial activity, toxicity is a fundamental param-
eter in possible future use. hLFcin1-11 has already been used in
different preclinical and clinical trials, where its overall safety was
proved (20, 22), and LFcin17-30 has been shown to be nontoxic
for erythrocytes and rat hepatocytes up to a 50 M concentration
(30). In the present work, we found that both the human and
bovine lactoferricins (hLFcin1-11 and LFcin17-30, respectively)
were active against M. avium strains of different virulences, the
bovine peptide being more active than the human one.
AMP vary widely in many aspects, such as length, sequence,
structure, and source, but they share important common traits,
such as a positive charge, presumed to be fundamental for inter-
action with the negatively charged surface of pathogen cells (4, 6),
and amphipathicity, which enables better interaction with the hy-
drophobic part of the microbial membrane, leading to its disrup-
tion (31, 32). Arginine residues were previously suggested to be
important for the antimicrobial activity of lactoferricins (5, 8, 29)
and also to potentiate the internalization of peptides (33–35).
Therefore, we studied lactoferricin variants with arginines re-
placed by lysines and vice versa. As shown in Table 1 and Fig. 2, all
peptides, human and bovine, with all arginines replaced by lysines
were less active against M. avium, whereas when lysines were re-
placed by arginines, the peptides were more active. This shows
that arginine residues are crucial for the antimicrobial activity of
these peptides against M. avium. The contribution of arginine for
activity is probably not charge related, since it bears the same
charge as lysine (1). The higher activities of peptides with argi-
nine residues could be the result of the presence of the bulky gua-
nidinium group on the side chain, enabling a better interaction
with the membranes, since multiple hydrogen bonds can in this
case be formed with the lipid headgroups around, whereas lysines
can interact with only one (5, 8, 33, 35, 36). Arginine can also
establish stronger cation- interactions, which occur mainly be-
tween aromatic residues (e.g., tryptophan) and residues with pos-
itively charged side chains (e.g., arginines and lysines), that could
allow the peptides to penetrate deeper into the membrane (8, 33,
35, 36). Moreover, arginines can form hydrogen bonds while es-
tablishing cation- interactions, with tryptophan, for instance,
whereas lysines cannot (8, 33, 35, 36). All these factors combined
may have contributed to a more efficient activity against myco-
bacteria (5, 8, 29, 33, 36).
Due to the large diversity of AMP and of their properties, there
is most probably no universal mechanism for their action. In this
work, we have contributed to the elucidation of the mechanism of
action of lactoferricins againstM. avium. Our observation that the
D enantiomer of LFcin17-30 is more active than the L form sug-
gests that antimycobacterial activity is not dependent on chiral
centers, such as specific protein receptors, which is in agreement
with previous observations made for lactoferricin and other AMP,
such as magainin, cecropin, melittin, and protegrin, against other
pathogens (5, 6, 37–39). One of the major drawbacks of the use of
AMP in the clinic is their susceptibility to proteases and other
plasma components, resulting in low metabolic stability and bio-
availability (40). One way to overcome this problem is to use D
peptides, which are more resistant to protease activity (32, 41).
This seems to be the case for LFcin17-30, which exhibited a higher
activity against M. avium with all D-amino acids, indicating that
FIG 2 Direct effect of lactoferricins on M. avium viability at 1, 2, and 4 days of incubation. M. avium 2447 SmT was incubated with hLFcin1-11, hLFcin1-11 all
K, LFcin17-30, D-LFcin17-30, LFcin17-30 all K, or LFcin17-30 all R at 0 and 12.5M.M. avium viability was determined by measuring CFU after 1, 2, and 4 days
of incubation. The results of one experiment out of three are shown.
Silva et al.
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this can be used advantageously in comparison to the L enan-
tiomer.
The concentration-effect curves obtained for the antimicrobial
activities of lactoferricins did not show a gradual decrease. Around
12.5 M, there was a sharp drop in mycobacterial viability, more
pronounced in the case of the bovine peptide, reflected in very
close values for IC50 and IC90. This observation is in line with some
models of AMP activity that predict the existence of a threshold
concentration for their antimicrobial activity (4).
M. avium is a slow-growing mycobacterium, and thus we used
7 days of culture to determine lactoferricin activity. However, pre-
vious reports showed that LFcin17-30 is able to exert antimicro-
bial activity against other pathogens in about 1 h (24, 42–44). In
order to evaluate the kinetics of the activity of lactoferricins
against M. avium, we performed several assays with shorter cul-
ture times. We did not observe any significant decrease in the
number of viable mycobacterial cells in less than 2 days of incu-
bation, with peptide concentrations up to 25 M (data not
shown). This “delay” in activity against M. avium compared to
that against other pathogens can be explained by the particular
characteristics of the mycobacterial cell wall, as well as an intrinsic
low rate of proliferation. Mycobacterium species are characterized
by a complex hydrophobic envelope of extremely low fluidity and
high impermeability, which contributes to the capacity of the
pathogen to survive inside the host and resist chemotherapy (45,
46). Furthermore, the possibility of an internal target for the action of
these peptides against M. avium cannot be discarded. In fact, there
are numerous evidences in the literature pointing to the probable
existence of an internal target for lactoferricins (5, 47–49).
Finally, electron microscopy studies showed that all lactoferri-
cin peptides tested induced significant changes both in the surface
and in the ultrastructural organization of the mycobacterial cells.
In agreement with the bacterial viability assays, D-LFcin17-30 and
the all-R variant showed the most drastic effects on the mycobac-
terial morphostructure. However, these studies did not allow us to
obtain definitive information on what is the target (or targets) of
the peptides. The observed accumulation of biological material
outside the cells, seen by both SEM and TEM, and the presence of
translucent cytoplasm and a high number of “ghost” cells (TEM)
indicate leakage and are compatible with cell membrane permea-
bilization. Clearer evidences that the peptides act by permeabili-
zation, such as the appearance of vesicular budding and disap-
pearance of the cell wall or membrane, were not observed. A
mechanism of action that includes crossing over the bacterial sur-
face and acting on internal targets has been proposed for bovine
lactoferricins. The higher activity of lactoferricins containing ar-
ginines also supports this hypothesis, since this amino acid is often
correlated with peptides that exert their activity on internal targets
(33–35), as opposed to lysines, which are usually described as cru-
FIG 3 Surface and ultrastructural alterations in M. avium induced by lacto-
ferricins at 2 days of incubation. M. avium 2447 SmT was incubated with
hLFcin1-11, hLFcin1-11 all K, LFcin17-30, D-LFcin17-30, LFcin17-30 all K, or
LFcin17-30 all R at 25M for 2 days. Cells were observed and photographed in
a scanning electron microscope (left panels) and in a transmission electron
microscope (right panels). Representative pictures are shown. Bar 1m (left
panels) or 0.5m (right panels). Symbols: arrow, shape deformations; arrow-
head, increased roughness and accumulation of intracellular material outside;
empty arrow, condensation of cytoplasmic material; asterisk, translucent cy-
toplasm and ghost cells.
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cial for membrane-lytic activities. In recent studies, we have
shown that LFcin17-30 has a mild effect on model membranes,
acting by lipid segregation instead of leading to full membrane
disruption, as observed for other membrane-active peptides (50).
Further, Haukland et al. (47) showed that lactoferricin is found in
the cytoplasm of Staphylococcus aureus and Escherichia coli, and
Ulvatne et al. (49) showed that it inhibits the macromolecular
synthesis (DNA, RNA, and protein synthesis) of E. coli and Bacil-
lus subtilis. The alterations seen suggest that the mechanism of
action of the studied lactoferricins against mycobacteria is not
confined to the cell wall or membrane but probably also includes
action on internal targets, leading to impairment of several intra-
cellular processes, such as DNA replication, DNA, RNA, and pro-
tein synthesis, protein folding, etc., which eventually culminates
in cell death.
In summary, key molecular features of lactoferricin-based
peptides for the display of antimycobacterial activity were identi-
fied, contributing to the understanding of their mechanism of
action against mycobacteria. Hence, this work demonstrates that
lactoferricin-related AMP are promising molecules for develop-
ment of clinically useful weapons to treat infections caused by
mycobacteria.
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